“减肥神药”热潮下,国内药企蓄势争夺千亿级GLP-1市场

华夏时报
12 Dec 2024

本报(chinatimes.net.cn)记者杨燕 北京报道随着各大电商平台的上线,原本只活跃在社交平台上的“减肥神药”越来越触手可及。12月9日,“GLP-1两大巨头”诺和诺德和礼来公司旗下的明星产品口服版司美格鲁肽(诺和忻)和替尔泊肽(穆峰达),在美团平台同一日开启全网首发预约通道,其中口服司美可下单,替尔泊肽可预约到店服务,周内有望开放预售送药到家。在此之前,减重版司美格鲁肽(诺和盈)也已于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10